TLR-4 Signaling Promotes Tumor Growth and Paclitaxel Chemoresistance in Ovarian Cancer

作者：Michael Greg Kelly, Ayesha B. Alvero, Rui Chen, Dan‐Arin Silasi, Vikki M. Abrahams, Serena Chan, Irene Visintin, Thomas Rutherford, Gil Mor · 发表于：Cancer Research · 年份：2006 · DOI：10.1158/0008-5472.can-05-3948 · 被引用次数：495 · 研究领域：Immune cells in cancer、Immune Response and Inflammation、Reproductive System and Pregnancy

Evidence suggests that an inflammatory profile of cytokines and chemokines persisting at a particular site would lead to the development of a chronic disease. Recent studies implicate bacterial infection as one possible link between inflammation and carcinogenesis; however, the crucial molecular pathways involved remain unknown. We hypothesized that one possible upstream signaling pathway leading to inflammation in carcinogenesis may be mediated by Toll-like receptors (TLR). We describe for the first time an adaptive mechanism acquired by ovarian cancer cells that allows them to promote a proinflammatory environment and develop chemoresistance. We propose that the TLR-4-MyD88 signaling pathway may be a risk factor for developing cancer and may represent a novel target for the development of biomodulators. Our work explains how bacterial products, such as lipopolysaccharide, can promote, directly from the tumor, the production of proinflammatory cytokines and the enhancement of tumor survival. In addition, we provide new evidence that links TLR-4 signaling, inflammation, and chemoresistance in ovarian cancer cells.